Expression of MAGE-C1/CT7 and MAGE-C2/CT10 Predicts Lymph Node Metastasis in Melanoma Patients

Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) R. Dummer et al.   ANNALS OF ONCOLOGY

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

(2010) O. Goodyear et al.   BLOOD

Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients

(2010) N. Nuber et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells

(2009) D. Atanackovic et al.   HAEMATOLOGICA

Improved Survival for Stage IV Melanoma From an Unknown Primary Site

(2009) Chris C. Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis

(2009) Bonnie E. Gould Rothberg et al.   JNCI-Journal of the National Cancer Institute

MAGE-C1/CT-7 expression in plasma cell myeloma: Sub-cellular localization impacts on clinical outcome

(2008) M. Tinguely et al.   CANCER SCIENCE

Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma

(2008) Marc-Oliver Riener et al.   INTERNATIONAL JOURNAL OF CANCER

Next Generation of Immunotherapy for Melanoma

(2008) John M. Kirkwood et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival After Lymphadenectomy for Nodal Metastasis From an Unknown Primary Melanoma

(2008) Chris C. Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemical characteristics of melanoma

(2008) Steven J. Ohsie et al.   JOURNAL OF CUTANEOUS PATHOLOGY

MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma

(2008) A Curioni-Fontecedro et al.   LEUKEMIA